TrialPloS one2022

A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.

Ann Logan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.